Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity

Habens, F., Srinivasan, N., Oakley, F., Mann, D.A., Ganesan, A. and Packham, G. (2005) Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity Apoptosis, 10, (3), pp. 481-491. (doi:10.1007/s10495-005-1877-0).


Full text not available from this repository.


The NF-kB transcription factor plays a key role in the regulation of apoptosis by modulating expression of a wide range of cell death control molecules. NF-kB also plays an important role in human diseases by promoting inappropriate cell survival. Small molecule inhibitors of NF-kB are therefore likely to provide novel therapeutic opportunities. Sulfasalazine (SFZ) is a synthetic anti-inflammatory comprising an aminosalicylate, 5-amino salicylic acid (5-ASA), linked to an antibiotic, sulfapyridine (SPY). SFZ, but not 5-ASA or SPY, inhibits activation of NF-kB. We synthesised a small number of SFZ analogues and determined their ability to inhibit NF-kB activity and promote apoptosis in chronic lymphocytic leukaemia and hepatic stellate cells, where NF-kB plays an important role in cell survival. Remarkably, 3 of the 6 analogues synthesised were significantly more effective (up to 8-fold) inhibitors of NF-kB dependent transcription and this increased activity was associated with enhanced apoptosis. Therefore, it is possible to readily improve the NF-kB inhibiting activity of SFZ and analogues of SFZ may be attractive therapeutic agents for malignancies and chronic liver disease where NF-kB is thought to play a significant role.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1007/s10495-005-1877-0
ISSNs: 1360-8185 (print)
Related URLs:
Keywords: apoptosis, chronic lymphocytic leukaemia, fibrosis, hepatic stellate cell, NF-kB, sulfasalazine

ePrint ID: 27081
Date :
Date Event
Date Deposited: 26 Apr 2006
Last Modified: 16 Apr 2017 22:31
Further Information:Google Scholar

Actions (login required)

View Item View Item